Global Leuprolide Market Growth (Status and Outlook) 2025-2031
Description
According to this study, the global Leuprolide market size will reach US$ million by 2031.
Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer"s disease.
United States market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Leuprolide players cover TOLMAR PHARMACEUTICALS, Sanofi, Teva, Sandoz (Novartis), Sun Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Leuprolide Industry Forecast” looks at past sales and reviews total world Leuprolide sales in 2024, providing a comprehensive analysis by region and market sector of projected Leuprolide sales for 2025 through 2031. With Leuprolide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leuprolide industry.
This Insight Report provides a comprehensive analysis of the global Leuprolide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Leuprolide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Leuprolide market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leuprolide and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leuprolide.
This report presents a comprehensive overview, market shares, and growth opportunities of Leuprolide market by product type, application, key players and key regions and countries.
Segmentation by Type:
Subcutaneous
Topical
Segmentation by Application:
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
Lee Pharma
Hanall
Please note: The report will take approximately 2 business days to prepare and deliver.
Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is also under investigation for possible use in the treatment of mild to moderate Alzheimer"s disease.
United States market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Leuprolide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Leuprolide players cover TOLMAR PHARMACEUTICALS, Sanofi, Teva, Sandoz (Novartis), Sun Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Leuprolide Industry Forecast” looks at past sales and reviews total world Leuprolide sales in 2024, providing a comprehensive analysis by region and market sector of projected Leuprolide sales for 2025 through 2031. With Leuprolide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Leuprolide industry.
This Insight Report provides a comprehensive analysis of the global Leuprolide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Leuprolide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Leuprolide market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Leuprolide and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Leuprolide.
This report presents a comprehensive overview, market shares, and growth opportunities of Leuprolide market by product type, application, key players and key regions and countries.
Segmentation by Type:
Subcutaneous
Topical
Segmentation by Application:
Breast Cancer
Endometriosis
Precocious Puberty
Prostate Cancer
Uterine Fibrosis
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
TOLMAR PHARMACEUTICALS
Sanofi
Teva
Sandoz (Novartis)
Sun Pharmaceutical
AbbVie
Bayer
Takeda
Beijing Boente Pharmaceutical
Livzon Pharmaceutical
Selleck
Hangzhou Peptide Biochemical
Chengdu Shenguo Biological Pharmaceutical
SciAnda Pharma
Daewoong
GP Pharm
Enteris BioPharma
Chong Kun Dang
Leadiant Biosciences
Hikma Pharmaceuticals
Lee Pharma
Hanall
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
150 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Leuprolide Market Size by Player
- 4 Leuprolide by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Leuprolide Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
